Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

9.1K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.1K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

4.5K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.5K
Cancer Survival Analysis01:21

Cancer Survival Analysis

559
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
559
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

10.7K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
10.7K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

5.6K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
5.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Feasibility and Oncologic Outcomes of Breast-Conserving Surgery for Multifocal and Multicentric Breast Cancer: A Retrospective Comparative Cohort Study.

Breast care (Basel, Switzerland)·2026
Same author

Polygenic Risk Scores for Breast Cancer Among African American Women With High Risk.

JAMA network open·2026
Same author

The second decade of DTI in TBI part 1: a systematic review of mild TBI.

Frontiers in neurology·2026
Same author

The second decade of DTI in TBI Part 2: a systematic review of moderate and severe TBI.

Frontiers in neurology·2026
Same author

Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Association of Polygenic-Based Breast Cancer Risk Prediction With Patient Management.

JCO precision oncology·2025
Same journal

Identification of a Novel <i>GOLGB1-RET</i> Fusion in Papillary Thyroid Cancer With a Durable Response to Selpercatinib.

JCO precision oncology·2026
Same journal

Cross-Platform Gene Signature to Predict Survival Outcomes for Nasopharyngeal Carcinoma.

JCO precision oncology·2026
Same journal

Perspectives From an Expert-Guided Discussion on Maximizing the Research Potential of Small Biopsy Tissue.

JCO precision oncology·2026
Same journal

Complete Response to Immune Checkpoint Inhibitor-Based Combination Therapy in PD-L1-High, Tumor Mutational Burden-Low Ovarian Sarcomatoid Squamous Cell Carcinoma.

JCO precision oncology·2026
Same journal

Emergence of Microsatellite Instability in an Oncogene-Driven Non-Small Cell Lung Cancer Harboring a Canonical <i>EGFR</i> Mutation: A Molecular Tumor Board Discussion.

JCO precision oncology·2026
Same journal

Frequency and Prognostic Significance of Genetic Abnormalities in a Subgroup of Patients With Intermediate-Risk Neuroblastoma: A SIOPEN Study.

JCO precision oncology·2026
See all related articles

Related Experiment Video

Updated: Dec 9, 2025

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.2K

Impact of a Cancer Gene Variant Reclassification Program Over a 20-Year Period.

Lisa Esterling1, Ranjula Wijayatunge2, Krystal Brown1

  • 1Myriad Genetic Laboratories, Salt Lake City, UT.

JCO Precision Oncology
|September 14, 2020
PubMed
Summary
This summary is machine-generated.

Hereditary cancer genetic testing identified and reclassified thousands of rare variants over 20 years. Novel laboratory tools were crucial for accurately assessing these variants, improving personalized cancer risk management.

More Related Videos

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.0K
gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair
08:15

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

Published on: October 6, 2014

12.6K

Related Experiment Videos

Last Updated: Dec 9, 2025

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.2K
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.0K
gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair
08:15

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

Published on: October 6, 2014

12.6K

Area of Science:

  • Genetics
  • Oncology
  • Bioinformatics

Background:

  • Hereditary cancer genetic testing is vital for personalized cancer risk management.
  • Evaluating the pathogenicity of rare variants in cancer predisposition genes presents challenges for traditional methods.

Purpose of the Study:

  • To analyze variant classification and reclassification trends over a 20-year period for hereditary cancer genes.
  • To assess the impact of novel laboratory-developed tools in variant reclassification.

Main Methods:

  • Retrospective analysis of over 1.9 million individuals undergoing hereditary cancer genetic testing.
  • Variant classification involved multidisciplinary expert review using traditional and laboratory-developed tools.
  • Tracking variant reclassifications, including upgrades and downgrades, over two decades.

Main Results:

  • Over 2,900 unique variants were reclassified across 25 cancer predisposition genes.
  • Most reclassifications were downgrades (82.1%), with many variants initially classified as variants of uncertain significance (VUS).
  • Laboratory-developed tools were instrumental, used in 72.3% of reclassifications affecting over 600,000 individuals.

Conclusions:

  • A robust variant classification program, utilizing novel tools, successfully reclassified individually rare variants.
  • Laboratory-developed tools are essential for accurate assessment of rare variants in hereditary cancer testing.
  • Effective reclassification of rare variants improves personalized medical management for cancer risk.